CN102762225B - 用于针对桦树过敏的疫苗的肽 - Google Patents

用于针对桦树过敏的疫苗的肽 Download PDF

Info

Publication number
CN102762225B
CN102762225B CN201180009545.3A CN201180009545A CN102762225B CN 102762225 B CN102762225 B CN 102762225B CN 201180009545 A CN201180009545 A CN 201180009545A CN 102762225 B CN102762225 B CN 102762225B
Authority
CN
China
Prior art keywords
seq
polypeptide
peptide
peptides
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180009545.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN102762225A (zh
Inventor
罗德里克·彼得·哈夫纳
保罗·莱德勒
盖伊·雷顿
马克·拉尔什
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Niox Healthcare Ltd
Original Assignee
Circassia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Circassia Ltd filed Critical Circassia Ltd
Publication of CN102762225A publication Critical patent/CN102762225A/zh
Application granted granted Critical
Publication of CN102762225B publication Critical patent/CN102762225B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
CN201180009545.3A 2010-02-15 2011-02-15 用于针对桦树过敏的疫苗的肽 Expired - Fee Related CN102762225B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1002559.1A GB201002559D0 (en) 2010-02-15 2010-02-15 Birch peptides for vaccine
GB1002559.1 2010-02-15
PCT/GB2011/000206 WO2011098778A2 (en) 2010-02-15 2011-02-15 Peptides for vaccines against birch allergy

Publications (2)

Publication Number Publication Date
CN102762225A CN102762225A (zh) 2012-10-31
CN102762225B true CN102762225B (zh) 2015-05-13

Family

ID=42110757

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180009545.3A Expired - Fee Related CN102762225B (zh) 2010-02-15 2011-02-15 用于针对桦树过敏的疫苗的肽

Country Status (20)

Country Link
US (2) US9017689B2 (enExample)
EP (2) EP3056213A1 (enExample)
JP (2) JP5926198B2 (enExample)
KR (1) KR20120120965A (enExample)
CN (1) CN102762225B (enExample)
AU (1) AU2011214104B2 (enExample)
CA (2) CA3139588A1 (enExample)
DK (1) DK2536429T3 (enExample)
EA (1) EA201290792A1 (enExample)
ES (1) ES2573651T3 (enExample)
GB (2) GB201002559D0 (enExample)
HR (1) HRP20160481T1 (enExample)
HU (1) HUE029138T2 (enExample)
IL (1) IL221196A0 (enExample)
MX (1) MX2012009431A (enExample)
NZ (1) NZ602380A (enExample)
PL (1) PL2536429T3 (enExample)
SG (1) SG183198A1 (enExample)
SI (1) SI2536429T1 (enExample)
WO (1) WO2011098778A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201002559D0 (en) * 2010-02-15 2010-03-31 Circassia Ltd Birch peptides for vaccine
JP2015509487A (ja) * 2012-02-07 2015-03-30 ラ ホーヤ インスティテュート フォー アレルギー アンド イムノロジーＬａ Ｊｏｌｌａ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ａｌｌｅｒｇｙ Ａｎｄ Ｉｍｍｕｎｏｌｏｇｙ アレルゲンタンパク質由来のエピトープ並びに免疫応答モジュレーションのための方法及び使用
GB201209862D0 (en) 2012-06-01 2012-07-18 Circassia Ltd Cladosporium peptides
GB201211586D0 (en) * 2012-06-29 2012-08-15 Circassia Ltd Japanese cedar peptides for preventing or treating allergy
US20150088644A1 (en) 2013-09-23 2015-03-26 Facebook, Inc., a Delaware corporation Predicting User Interactions With Objects Associated With Advertisements On An Online System
CN106699584B (zh) * 2016-12-30 2018-06-26 南京农业大学 一种利用花粉作为天然催化剂制备的γ-氨基丁酸及其制备方法和应用
NZ759513A (en) 2017-06-01 2022-01-28 Regeneron Pharma Human antibodies to bet v 1 and methods of use thereof
CN110175468B (zh) * 2019-05-05 2020-12-01 浙江工业大学 一种保留分布特征的姓名脱敏方法
CN115633666B (zh) * 2021-07-19 2025-11-18 四川大学华西医院 人源化双致敏动物模型和系统性过敏动物模型的构建方法及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004081028A2 (en) * 2003-03-14 2004-09-23 University Of Lausanne Allergen peptide fragments and use thereof
WO2009022154A2 (en) * 2007-08-15 2009-02-19 Circassia Limited Peptide with multiple epitopes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
WO1994001560A1 (en) 1991-07-12 1994-01-20 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from japanese cedar pollen
US5968526A (en) 1994-04-14 1999-10-19 Immulogic Pharamaceutical Corporation T cell epitopes of the major allergens from Dermatophagoides (house dust mite)
WO1999034826A1 (en) 1998-01-09 1999-07-15 Circassia Limited Methods and compositions for desensitisation
FR2788698B1 (fr) 1999-01-27 2001-03-30 Commissariat Energie Atomique Peptides et proteines aptes a desensibiliser les sujets allergiques au venin d'abeille et compositions les contenant
ES2316632T3 (es) 2001-12-05 2009-04-16 Circassia Limited Metodos y sistemas inmunoterapeuticos.
PT1403280E (pt) 2002-09-27 2005-11-30 Biomay Prod & Handel Vacinas hipoalergenicas baseadas no alergenio ph1 p 7 de polen de capim timoteo
ES2425486T3 (es) 2007-05-09 2013-10-15 Circassia Limited Análisis de pronóstico para determinar la respuesta de células T a antígenos HLA y uso del mismo en el campo del trasplante de tejidos
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
US8821887B2 (en) 2008-08-15 2014-09-02 Circassia Limited T-cell antigen peptide from allergen for stimulation of IL-10 production
GB201002559D0 (en) * 2010-02-15 2010-03-31 Circassia Ltd Birch peptides for vaccine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004081028A2 (en) * 2003-03-14 2004-09-23 University Of Lausanne Allergen peptide fragments and use thereof
WO2009022154A2 (en) * 2007-08-15 2009-02-19 Circassia Limited Peptide with multiple epitopes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Intranasal tolerance induction with polypeptides derived from 3 noncross-reactive major aeroallergens prevents allergic polysensitization in mice;Karin Hufnagl 等;《Journal of Allergy and Clinical Immunology》;20050831;第116卷(第2期);370-376 *
Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination;M. Focke 等;《Clin Exp Allergy》;20041231;第34卷;1525-1533 *
P35079;Valenta,R.等;《Genbank》;20091124;全序列 *

Also Published As

Publication number Publication date
MX2012009431A (es) 2012-09-12
GB201102657D0 (en) 2011-03-30
US9017689B2 (en) 2015-04-28
AU2011214104A1 (en) 2012-09-06
CA2789353A1 (en) 2011-08-18
EA201290792A1 (ru) 2013-03-29
GB2481475B (en) 2012-09-19
KR20120120965A (ko) 2012-11-02
GB2481475A (en) 2011-12-28
US20130243798A1 (en) 2013-09-19
AU2011214104B2 (en) 2015-05-28
IL221196A0 (en) 2012-10-31
ES2573651T3 (es) 2016-06-09
NZ602380A (en) 2014-10-31
SI2536429T1 (sl) 2016-08-31
WO2011098778A2 (en) 2011-08-18
CA3139588A1 (en) 2011-08-18
JP2016166194A (ja) 2016-09-15
JP2013519717A (ja) 2013-05-30
US20150196635A1 (en) 2015-07-16
WO2011098778A3 (en) 2011-12-15
HUE029138T2 (hu) 2017-02-28
HRP20160481T1 (hr) 2016-06-03
HK1165700A1 (en) 2012-10-12
CN102762225A (zh) 2012-10-31
EP2536429B1 (en) 2016-02-10
SG183198A1 (en) 2012-09-27
DK2536429T3 (en) 2016-05-23
JP5926198B2 (ja) 2016-05-25
GB201002559D0 (en) 2010-03-31
WO2011098778A8 (en) 2012-09-27
EP3056213A1 (en) 2016-08-17
PL2536429T3 (pl) 2016-09-30
EP2536429A2 (en) 2012-12-26

Similar Documents

Publication Publication Date Title
CN103272227B (zh) 针对过敏原去敏化的肽
CN102762225B (zh) 用于针对桦树过敏的疫苗的肽
CN102170897B (zh) 用于治疗豚草变态反应的包含Amb a 1肽的疫苗
CN103784952B (zh) 用于疫苗的草肽
AU2013202362B2 (en) Grass Peptides for Vaccine
AU2013203568B2 (en) Peptides for desensibilization against allergens
AU2013269327A1 (en) Cladosporium peptides
HK1197371A (en) Grass peptides for vaccine
HK1164700B (en) Peptides for desensibilization against allergens

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150513

CF01 Termination of patent right due to non-payment of annual fee